Personalis

Personalis PSNL Stock

$14.71   -0.608109%
Add to favorites
Market Cap
$1.59B
LOW - HIGH [24H]
$14.70 - $14.95
VOLUME [24H]
$497.76K
P/E Ratio
0
Earnings per share
-$1.16
ISIN
US71535D1063
Price   Prediction

Personalis Price Chart

Sorry, that's all we've gotfor now...

Personalis (PSNL) stock price today is 14.71 USD on Tech Market Middle (-0.61% on the day). Updated .

Personalis PSNL Financial and Trading Overview

Personalis stock price 14.71 USD
Previous Close 14.8 USD
Open 14.81 USD
Bid 9.7 USD x 200
Ask 17.35 USD x 200
Day's Range 14.52 - 15.02 USD
52 Week Range 4.96 - 18.89 USD
Volume 3.13M USD
Avg. Volume 2.84M USD
Market Cap 1.6B USD
Beta (5Y Monthly) 2.36
PE Ratio (TTM) N/A
EPS (TTM) -1.16 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 15.17 USD

PSNL Valuation Measures

Enterprise Value 1.45B USD
Trailing P/E N/A
Forward P/E -15.071283
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 19.86352
Price/Book (mrq) 7.543323
Enterprise Value/Revenue 17.964
Enterprise Value/EBITDA -12.422

Trading Information

Personalis Stock Price History

Beta (5Y Monthly) 2.36
52-Week Change 79.61%
S&P500 52-Week Change 10.51%
52 Week High 18.89 USD
52 Week Low 4.96 USD
50-Day Moving Average 15.99 USD
200-Day Moving Average 11.63 USD

PSNL Share Statistics

Avg. Volume (3 month) 2.84M USD
Avg. Daily Volume (10-Days) 2.84M USD
Shares Outstanding 108.4M
Float 73.9M
Short Ratio 2.96
% Held by Insiders 25.60%
% Held by Institutions 66.87%
Shares Short 6.75M
Short % of Float 9.64%
Short % of Shares Outstanding 6.21%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -147.73%
Operating Margin (ttm) -156.66%
Gross Margin 16.70%
EBITDA Margin -144.62%

Management Effectiveness

Return on Assets (ttm) -29.59%
Return on Equity (ttm) -62.13%

Income Statement

Revenue (ttm) 80.77M USD
Revenue Per Share (ttm) 0.79 USD
Quarterly Revenue Growth (yoy) 76.59%
Gross Profit (ttm) 13.49M USD
EBITDA -116810000 USD
Net Income Avi to Common (ttm) -119328000 USD
Diluted EPS (ttm) -1.16
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 190.6M USD
Total Cash Per Share (mrq) 1.76 USD
Total Debt (mrq) 37.2M USD
Total Debt/Equity (mrq) 17.49 USD
Current Ratio (mrq) 4.527
Book Value Per Share (mrq) 1.962

Cash Flow Statement

Operating Cash Flow (ttm) -97566000 USD
Levered Free Cash Flow (ttm) -59346624 USD

Profile of Personalis

Country United States
State CA
City Fremont
Address 6600 Dumbarton Circle
ZIP 94555
Phone 650 752 1300
Website https://www.personalis.com
Industry Diagnostics & Research
Sector(s) Healthcare
Full Time Employees 259

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Q&A For Personalis Stock

What is a current PSNL stock price?

Personalis PSNL stock price today per share is 14.71 USD.

How to purchase Personalis stock?

You can buy PSNL shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Personalis?

The stock symbol or ticker of Personalis is PSNL.

Which industry does the Personalis company belong to?

The Personalis industry is Diagnostics & Research.

How many shares does Personalis have in circulation?

The max supply of Personalis shares is 108.4M.

What is Personalis Price to Earnings Ratio (PE Ratio)?

Personalis PE Ratio is now.

What was Personalis earnings per share over the trailing 12 months (TTM)?

Personalis EPS is -1.16 USD over the trailing 12 months.

Which sector does the Personalis company belong to?

The Personalis sector is Healthcare.

Personalis PSNL included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24399.9 USD —
+0.29
2.79B USD — 24268.03 USD — 24538.78 USD — — 2.79B USD —
us US Tech Global Market Composite NQGM US 1833.55 USD —
-0.12
— — 1832.56 USD — 1855.92 USD — — — —
us US Tech Biotechnology NBI US 6969.93 USD —
-0.68
— — 6959.96 USD — 7076.43 USD — — — —
us US Tech Health Care IXHC US 1324.33 USD —
-0.64
— — 1322.85 USD — 1342.46 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.18T
Total marketcap
$68.49B
Total volume
BTC 58.12%   •   ETH 9.91%
Dominance
Select currency